Scientists test new combo against aggressive blood cancers
NCT ID NCT03878199
Summary
This study tested a combination of two drugs, ruxolitinib and CPX-351, for patients with advanced forms of certain blood cancers that had worsened. The main goals were to find the safest dose of the combination and to see how well it worked to control the cancer. The trial involved a small group of 12 participants who had not responded well to prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU
Portland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Simmons Cancer Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.